In the fourth quarter of 2013 a total of 15,327,405 B shares of DKK 0.20 were repurchased, and 1,940,620 B shares of DKK 0.20 were disposed of to employees in connection with employee incentive programmes.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B
shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further information Media: Anne Margrethe Hauge Ken Inchausti (US) | +45 4442 3450 +1 609 514 8316 | amhg@novonordisk.com kiau@novonordisk.com |
Investors: Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen Jannick Lindegaard (US) | +45 3079 0604 +45 3075 3479 +45 3079 6376 +1 609 235 8567 | fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Company announcement No 1 / 2014
distributed by |